文献速递淋巴瘤白血病

非霍奇金淋巴瘤和慢性淋巴细胞白血病患者接种mRNA疫苗后对SARS-CoV-2及关注变异株的体液反应

Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
PubMed 文献 · J Clin Oncol · 2022-04-18

本研究纵向采集121例接受两剂疫苗的非霍奇金淋巴瘤/慢性淋巴细胞白血病(NHL/CLL)患者血样,检测对原始株及Delta、Omicron变异株的抗体结合与活病毒中和能力。患者抗体结合滴度较健康对照低85倍,仅67%发生血清转换;末次抗CD20治疗1年内结合滴度低136倍,B细胞计数≥4.31/μL可预测应答(OR 7.46,P=.04)。

要点

  • NHL/CLL患者接种mRNA疫苗后抗体结合滴度较健康对照低85倍,血清转换率仅67%。
  • 末次抗CD20治疗1年内结合滴度低136倍,B细胞计数≥4.31/μL预测应答(OR 7.46,P=.04)。
  • 对Delta和Omicron的中和滴度分别降低6倍和42倍,67% WA1/2020血清阳性者对Omicron血清阴性。

核心结论

  • NHL/CLL患者对SARS-CoV-2及其关注变异株(包括Delta和Omicron)的抗体结合和活病毒中和反应均显著低于健康接种者。
  • 接种前1年内接受抗CD20靶向治疗及循环B细胞数量可强烈预测疫苗应答。

研究设计与样本

  • 纵向采集121例接受两剂疫苗的NHL/CLL患者血液样本。
  • 采用多重检测法测定针对原始株及变异株全长刺突蛋白、受体结合域和N端结构域的抗体结合。
  • 采用聚焦减少中和试验测定对Delta、Omicron和早期WA1/2020株的活病毒中和能力。
  • 通过流式细胞术检测B细胞,并分析疫苗应答与临床因素的相关性。

主要发现

  • NHL/CLL患者抗SARS-CoV-2刺突蛋白IgG结合滴度均值较健康对照低85倍,仅67%患者发生血清转换。
  • 中和滴度也较低,且与结合滴度相关(P < .0001)。
  • 1年内接受抗CD20靶向治疗者结合滴度低136倍。
  • 外周血B细胞计数与疫苗应答相关;末次抗CD20治疗后3个月,疫苗接种前后B细胞计数≥4.31/μL可预测应答(OR 7.46,P = .04)。
  • 抗体应答还与年龄相关;对Delta和Omicron的中和滴度分别降低6倍和42倍,67%的WA1/2020血清阳性患者对Omicron血清阴性。

关键数值与推荐

  • NHL/CLL患者较健康对照:抗SARS-CoV-2刺突蛋白IgG结合滴度均值低85倍,血清转换率67%。
  • 1年内接受抗CD20靶向治疗者较未接受者:结合滴度低136倍。
  • 末次抗CD20治疗后3个月,B细胞计数≥4.31/μL者疫苗应答的OR为7.46(P = .04)。
  • 对Delta和Omicron的中和滴度分别较WA1/2020降低6倍和42倍;67%的WA1/2020血清阳性患者对Omicron血清阴性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with non-Hodgkin lymphoma including chronic lymphocytic leukemia (NHL/CLL) are at higher risk of severe SARS-CoV-2 infection. We investigated vaccine-induced antibody responses in patients with NHL/CLL against the original SARS-CoV-2 strain and variants of concern including B.1.167.2 (Delta) and B.1.1.529 (Omicron). MATERIALS AND METHODS: Blood from 121 patients with NHL/CLL receiving two doses of vaccine were collected longitudinally. Antibody binding against the full-length spike protein, the receptor-binding, and N-terminal domains of the original strain and of variants was measured using a multiplex assay. Live-virus neutralization against Delta, Omicron, and the early WA1/2020 strains was measured using a focus reduction neutralization test. B cells were measured by flow cytometry. Correlation between vaccine response and clinical factors was determined. RESULTS: Mean anti-SARS-CoV-2 spike immunoglobulin G-binding titers were 85-fold lower in patients with NHL/CLL compared with healthy controls, with seroconversion occurring in only 67% of patients. Neutralization titers were also lower and correlated with binding titers (P < .0001). Treatment with anti-CD20-directed therapies within 1 year resulted in 136-fold lower binding titers. Peripheral blood B-cell count also correlated with vaccine response. At 3 months from last anti-CD20-directed therapy, B-cell count ≥ 4.31/μL blood around the time of vaccination predicted response (OR 7.46, P = .04). Antibody responses also correlated with age. Importantly, neutralization titers against Delta and Omicron were reduced six- and 42-fold, respectively, with 67% of patients seropositive for WA1/2020 exhibiting seronegativity for Omicron. CONCLUSION: Antibody binding and live-virus neutralization against SARS-CoV-2 and its variants of concern including Delta and Omicron were substantially lower in patients with NHL/CLL compared with healthy vaccinees. Anti-CD20-directed therapy < 1 year before vaccination and number of circulating B cells strongly predict vaccine response.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chang A, Akhtar A, Linderman SL, et al. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. J Clin Oncol. 2022. PMID: 35436146. doi:10.1200/JCO.22.00088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。